SCHEMBL511015

SCHEMBL511015

Brc1cnn(C(c2ccccc2)(c2ccccc2)c2ccccc2)c1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
KCNN4 O15554 1/20 0.36
KCNA3 P22001 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
ELANE P08246 4/20 0.35
PLAU P00749 3/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
F2 P00734 1/20 0.30
KLKB1 P03952 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7256256 0.86 AKT1 (0.34) ALDH1A1HPGD
SCHEMBL2387915 0.78 KDM4E (0.41) ALDH1A1HPGDMAPK1KMT2A
SCHEMBL31428680 0.77 GABRG2 (0.43) ALDH1A1HPGDTSHRKMT2A
SCHEMBL7254281 0.77 GAA (0.48) ALDH1A1KCNN4KCNA3CYP11B1CYP11B2
SCHEMBL29771432 0.77 L3MBTL1 (0.41) KCNN4KCNA3CYP11B1CYP11B2HPGD
SCHEMBL27743631 0.77 MAPT (0.37) ALDH1A1KCNN4KCNA3CYP11B1CYP11B2
SCHEMBL8313319 0.77 KCNN4 (0.36) KCNN4KCNA3CYP11B1CYP11B2
SCHEMBL70574 0.77 L3MBTL1 (0.44) ALDH1A1KCNN4KCNA3CYP11B1CYP11B2
SCHEMBL21233040 0.77 KDM4E (0.39) ALDH1A1KCNN4KCNA3CYP11B1CYP11B2
SCHEMBL69872 0.77 KCNN4 (0.36) KCNN4KCNA3CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS INC (US) 2026-04-30 US disclosed
EP-3623372-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH INC (US) 2026-02-04 EP disclosed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 EP disclosed
US-12263171-B2 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use MERCK SHARP & DOHME LLC (US) 2025-04-01 US disclosed
WO-2025036269-A1 COMPOUND, COMPOSITION COMPRISING SAME, AND USE THEREOF 青岛普泰科生物医药科技有限公司 2025-02-20 WO disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed
CN-118994001-A NOTCH signaling pathway inhibitors and their use in cancer treatment 塞莱斯蒂亚生物技术股份公司 2024-11-22 CN disclosed
CN-113966324-B NOTCH signaling pathway inhibitors and their use in cancer treatment 塞莱斯蒂亚生物技术股份公司 2024-09-03 CN disclosed
US-20240268216-A1 TETRADENTATE PLATINUM AND PALLADIUM COMPLEX EMITTERS CONTAINING PHENYL-PYRAZOLE AND ITS ANALOGUES UNIV ARIZONA STATE (US) 2024-08-08 US disclosed
EP-1109799-A1 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS PACIFIC CORPORATION (KR) 2001-06-27 EP disclosed
US-6200978-B1 FOR PREVENTING OR TREATING INFLAMMATORY DISEASES SUCH AS ARTHRITIS, PSORIASIS, ASTHMA, OR INFLAMMATORY BOWEL DISEASE, DISORDERS OF RESPIRATORY FUNCTION, GASTROINTESTINAL DISORDERS SUCH AS FUNCTIONAL BOWEL DISEASE, AS ANALGESICS PFIZER INC. 2001-03-13 US disclosed
WO-2000061571-A1 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS PACIFIC CORPORATION (KR) 2000-10-19 WO disclosed
US-6015825-A Triazole antifungal agents PFIZER INC. (US) 2000-01-18 US disclosed
CN-1189162-A Triazole anti-fungal agents PFIZER RES & DEV (IE) 1998-07-29 CN disclosed
WO-1997001552-A1 TRIAZOLE ANTIFUNGAL AGENTS PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) 1997-01-16 WO disclosed
WO-1996010559-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-11 WO disclosed
EP-0586632-A1 BENZODIAZEPINONES AND MEDICINES CONTAINING THEM F. HOFFMANN-LA ROCHE AG (CH) 1994-03-16 EP disclosed
EP-0574781-A2 2-Amino-5-heterocyclic-substituted-1,4-benzodiazepines and their use in the treatment of aids F. HOFFMANN-LA ROCHE AG (CH) 1993-12-22 EP disclosed
WO-1993017010-A1 BENZODIAZEPINONES AND MEDICINES CONTAINING THEM F.HOFFMANN-LA ROCHE AG (CH) 1993-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE KIF2C, KIF5B, KIF5C ALDH1A1 2556/4885KCNN4 2007/4885KCNA3 1008/4885
US-20240268216-A1 TETRADENTATE PLATINUM AND PALLADIUM COMPLEX EMITTERS CONTAINING PHENYL-PYRAZOLE AND ITS ANALOGUES PDCD1, PDCD11, TYMP ALDH1A1 1517/4885KCNN4 3054/4885KCNA3 2706/4885
US-12263171-B2 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use ADORA2A, ADORA2B, ADORA3 ALDH1A1 1156/4885KCNN4 1990/4885KCNA3 1234/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 ALDH1A1 4472/4885KCNN4 4519/4885KCNA3 4280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.